Latanoprost for uncontrolled glaucoma in a compassionate case protocol

American Journal of Ophthalmology
B PatelskaR Ritch

Abstract

To evaluate the ocular hypotensive response of latanoprost 0.005% administered as adjunctive therapy in patients with glaucoma who were receiving maximal tolerated medical therapy. Consecutive patients entering a latanoprost compassionate clinical trial were enrolled at two sites. Latanoprost 0.005% was administered as a single drop between 6 and 8 PM, and all other medications were continued. Intraocular pressure was measured between 2 and 4 PM. Responders were defined as having a reduction in intraocular pressure of at least 20% from baseline. In 160 eyes of 160 patients, mean baseline intraocular pressure +/- SD was 23.3 +/- 6.9 mm Hg. Intraocular pressure was significantly reduced compared with baseline measurements (P < .01) with mean intraocular pressure measurement reductions of 4.1 +/- 5.2, 4.0 +/- 6.3, and 3.7 +/- 4.2 mm Hg at the 1-, 3-, and 6-month intervals, respectively. A reduction in intraocular pressure of at least 20% was observed in 64 (44.4%) of 144 patients, 46 (43.0%) of 107 patients, and 10 (32.3%) of 31 patients at the 1-, 3-, and 6-month visits, respectively. A 40% reduction in intraocular pressure was observed in 18 (12.5%) of 144 and nine (8.4%) of 107 patients at 1 and 3 months, respectively. Mean red...Continue Reading

References

Sep 1, 1989·Experimental Eye Research·B T Gabelt, P L Kaufman
Nov 1, 1971·Experimental Eye Research·A Bill, C I Phillips
Jan 22, 1993·Journal of Medicinal Chemistry·B ResulL Z Bito

❮ Previous
Next ❯

Citations

Jul 20, 2000·Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie·B DesMarchaisM B Shields
Sep 22, 2001·Journal of Cataract and Refractive Surgery·M WandM B Shields
Sep 3, 2002·Survey of Ophthalmology·Remo SusannaYoshiaki Kitazawa
Sep 3, 2002·Survey of Ophthalmology·Laura B Enyedi, Sharon F Freedman
Sep 3, 2002·Survey of Ophthalmology·Carol B TorisCarl B Camras
Dec 4, 2001·American Journal of Ophthalmology·S L MansbergerG A Cioffi
Jun 1, 2001·American Journal of Ophthalmology·C B TorisM E Yablonski
Jan 18, 2006·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Esther Arranz-Marquez, Miguel A Teus
Apr 3, 2001·Expert Opinion on Investigational Drugs·C Lindén
Apr 3, 2001·Expert Opinion on Investigational Drugs·L B Cantor
Mar 11, 1999·Journal of AAPOS : the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus·L B EnyediE G Buckley
Apr 21, 2004·Journal of Glaucoma·Arvind NeelakantanMark B Sherwood
Mar 17, 2004·Current Opinion in Ophthalmology·Velota C T Sung, Keith Barton
Jan 5, 2002·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Y TamakiA Tomidokoro
Feb 27, 1999·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·S L SmithW C Stewart
Jan 23, 2003·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Kirk N Gelatt, Edward O Mackay
Jun 17, 2006·Journal of Glaucoma·Luca RossettiNicola Orzalesi
Jul 2, 2005·Journal of Glaucoma·Atilla BayerGeorge L Spaeth
Feb 22, 2012·Expert Opinion on Pharmacotherapy·Maurizio DigiuniLuca Rossetti
Oct 18, 2019·Wiley Interdisciplinary Reviews. Developmental Biology·Karen M Downs, Adriana M Rodriguez
Feb 27, 2015·Ophthalmic Plastic and Reconstructive Surgery·Philip L Custer, Tiffany L Kent
Feb 27, 2001·Current Opinion in Ophthalmology·R Susanna, F A Medeiros
Mar 16, 2001·Expert Opinion on Pharmacotherapy·A W Talbot, I Russell-Eggitt
Oct 3, 2003·Expert Opinion on Pharmacotherapy·Ciro CostagliolaAdolfo Sebastiani
May 3, 2000·Seminars in Ophthalmology·T W Hejkal, C B Camras
Jul 12, 2007·Ophthalmic Research·Yisheng ZhongQin Jiao
Aug 3, 2010·Current Eye Research·K G SchmidtOrna Geyer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.